ANI Pharma says Phase 4 SYNCHRONICITY trial meets co-primary endpoints for ILUVIEN in chronic posterior uveitis

• ANI Pharmaceuticals reported positive Phase 4 SYNCHRONICITY trial results for ILUVIEN in chronic non-infectious posterior segment uveitis.
• Six-month and two-year findings were already presented as a late-breaking oral session at the American Academy of Ophthalmology 2026 meeting.
• Study met both co-primary endpoints, showing improved vision and reduced retinal swelling that held through 24 months.
• Most patients had no inflammation recurrence over two years, supporting a durable effect from a single implant.
• Safety profile matched prior experience, with eye-pressure increases and cataracts among the main treatment-related events.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ANI Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120655PRIMZONEFULLFEED9843506) on October 12, 2026, and is solely responsible for the information contained therein.